Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-center, single-arm, phase II study

被引：0
|
作者：
Zhao, Y. [1 ]
Wang, L. [1 ]
Mao, A. [1 ]
Zhang, T. [1 ]
Pan, Q. [1 ]
Wang, L. [1 ]
Wang, Y. [1 ]
Lin, Z. [1 ]
Zhang, N. [1 ]
Zhou, J. [1 ]
Wang, M. [1 ]
Zhang, Y. [1 ]
Feng, Y. [1 ]
Ding, Z. [1 ]
Wang, Y. [1 ]
Li, Y. [1 ]
Wu, Z. [1 ]
机构：
[1] Fudan Univ, Hepat Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
136P
引用
收藏
页码：S1458 / S1458
页数：1
相关论文
共 50 条
  • [1] Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
    Guo-Ming Shi
    Xiao-Yong Huang
    Dong Wu
    Hui-Chuan Sun
    Fei Liang
    Yuan Ji
    Yi Chen
    Guo-Huan Yang
    Jia-Cheng Lu
    Xian-Long Meng
    Xin-Ying Wang
    Lei Sun
    Ning-Ling Ge
    Xiao-Wu Huang
    Shuang-Jian Qiu
    Xin-Rong Yang
    Qiang Gao
    Yi-Feng He
    Yang Xu
    Jian Sun
    Zheng-Gang Ren
    Jia Fan
    Jian Zhou
    Signal Transduction and Targeted Therapy, 8
  • [2] Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
    Shi, Guo-Ming
    Huang, Xiao-Yong
    Wu, Dong
    Sun, Hui-Chuan
    Liang, Fei
    Ji, Yuan
    Chen, Yi
    Yang, Guo-Huan
    Lu, Jia-Cheng
    Meng, Xian-Long
    Wang, Xin-Ying
    Sun, Lei
    Ge, Ning-Ling
    Huang, Xiao-Wu
    Qiu, Shuang-Jian
    Yang, Xin-Rong
    Gao, Qiang
    He, Yi-Feng
    Xu, Yang
    Sun, Jian
    Ren, Zheng-Gang
    Fan, Jia
    Zhou, Jian
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [3] Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer
    Wang, Longrong
    Zhang, Ning
    Wang, Yixiu
    Zhang, Ti
    Zhu, Weiping
    Mao, Anrong
    Zhao, Yiming
    Wang, Lu
    CANCER MEDICINE, 2023, 12 (11): : 12263 - 12271
  • [4] Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
    Liu, Dechun
    Yan, Tao
    Zhang, Qian
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S89 - S90
  • [5] Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer
    Wang, L.
    Wang, L.
    Zhang, T.
    Zhao, Y.
    Mao, A.
    Zhu, W.
    Zhang, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S288 - S288
  • [6] TISLELIZUMAB IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER, SINGLE-ARM, EXPLORATORY PHASE I I CLINICAL STUDY
    Laoguo, Shixue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, Guangzhi
    Ma, Fuchao
    Peng, Tao
    Yang, Lihua
    Zeng, Zhiming
    Ma, Jie
    HEPATOLOGY, 2023, 78 : S1904 - S1904
  • [7] Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study
    Liu, Wenlou
    Wang, Hongmei
    Zhao, Yang
    Ge, Yan
    Tang, Juangjuang
    Cao, Menghan
    Matsas, Silvio
    Breadner, Daniel Adam
    Qin, Xiaobing
    Han, Zhengxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
  • [8] Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.
    Kong, Wen
    Wu, Guangyu
    Xu Sr, Yunze
    Wang, Zaoyu
    Zhang, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [9] Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study)
    Kuang, Ming
    Xu, Lixia
    Zhang, Mengping
    Zheng, Gaomin
    Zhang, Chuankai
    Zhang, Ying
    Su, Tianhong
    Wang, Jifei
    Wang, Fang
    Wang, Fengjie
    Chen, Huanwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers
    Li, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S570 - S570
12345